Clinical navigation · the holding phase
The maintenance dose conversation: the options, the evidence, and the money math nobody prices for you
Maintenance is the phase with the least marketing and the most patients: the goal range reached, the project now holding it — and the conversation with your prescriber has a real option space. Option one, stay the course: the current effective dose continues — the best-evidenced choice, since the withdrawal trials show continuing preserves what stopping surrenders. Option two, step down: find the lowest dose that holds — clinically common, evidence thinner than option one, run as a monitored experiment with a written revert threshold. Option three, stretch the interval: some prescribers individualize beyond weekly dosing in maintenance — an off-label pattern the labels don’t specify and the evidence base only sketches; it exists, it’s your clinician’s call, and it’s named here so the conversation can include it honestly. Then the dimension nobody prices for you: maintenance is where pricing architecture bites hardest — dose-tier programs charge their maximum exactly when you’re parked at an effective dose forever, while flat dose-proof pricing costs the same at month 30 as month 3. The full conversation script, the monitoring rhythm, and the money math below.
The three options — evidence-weighted, not equal
Stay: the discontinuation studies are the case — stop and, on average, a large share of loss returns within a year; continue and the hold is durable for most. Staying at the effective dose is the default that needs no defense, only tolerability and budget. Step down: the logic is sound (lowest effective dose is good medicine), the direct trial evidence for GLP-1 maintenance-at-reduced-dose is thinner than patients assume, and the honest structure is experimental: one step down, eight-to-twelve weeks of tight monitoring, and a pre-written revert threshold (“if I regain X lb or hunger noise returns to Y, we step back up”) — thresholds written calm get honored, per the exit file’s same rule. Stretch: extended intervals in maintenance exist in real-world practice and the pharmacology (long half-lives) explains why it can work for some — and it remains off-label individualization with sketchy comparative data, which is exactly how your prescriber should present it if they offer it. What’s not on the list: improvising any of the three alone — every option is a monitored clinical structure, not a vibe.
The conversation script — five minutes, structured
Open with the reframe so the visit has the right frame: “I’m at [weight], holding [N] weeks — I’d like to plan maintenance rather than keep default-continuing.” Then the four questions: “Given my history, which of stay / step-down / interval do you recommend and why? If we trial a reduction, what monitoring cadence and what revert threshold would you set? What does my lab picture suggest — anything that argues for or against a change? And what’s our re-escalation plan if the trial fails — dose path and timeline?” Bring the artifacts that make the answer smart: the photo timeline, the weight log, the side-effect map from the archive. And close with the calendar: maintenance decisions get review dates (twelve weeks is a common rhythm), because “we’ll see how it goes” without a date is how experiments become drifts — the anniversary letter then audits the year’s worth.
Monitoring in maintenance — lighter, not looser
The surveillance load drops; the structure shouldn’t vanish. Weight: weekly same-conditions weigh-ins continue (maintenance drift announces itself in three-pound whispers), logged in the same archive. The band, pre-agreed: a ± range around your hold weight (commonly a few pounds) inside which nothing changes and outside which the plan’s next step triggers — bands prevent both panic-at-noise and denial-at-drift. Labs: annually for most in stable maintenance, per your clinician — the improved lines from the loss phase are worth confirming they held. Photos and measurements: the monthly protocol continues — recomposition keeps happening in maintenance, and it’s the evidence that makes a stable scale feel like the victory it is. Behavioral floor: the protein band and resistance work from the kitchen file are the actual maintenance mechanism the medication assists — they don’t retire when the losing stops.
The money math — where architecture decides the decade
Run the maintenance decade, because that’s the honest horizon of a chronic tool. Tier architecture: dose-scaled programs price maintenance at your dose’s rung — commonly the upper rungs, since effective doses skew upward — so “$199 entering” programs frequently bill $299-class forever, which is $3,588/year and ~$35,900 over ten (before the price drift the renewal review exists to catch). Flat dose-proof architecture: the audited pair holds at $119/$139 regardless of dose — $1,428/$1,668 a year, ~$14,300–$16,700 over ten (compounded; not FDA-approved) — which is the structural reason maintenance-phase patients dominate the consolidation and switch traffic on the index. Coverage, always first: a covered brand at ~$25-class copays beats every cash lane in maintenance too, and maintenance’s stable, documented years are the strongest prior-auth story you’ll ever file. The one-sentence version for the prescriber visit’s parking lot: clinically, choose the option with the best evidence for you; financially, make sure the plan you’re parked on was built for parking. Flat at every dose — built for the holding years ↗
FAQ
Do I stay on the same GLP-1 dose for maintenance?
Staying at the effective dose is the best-evidenced default; stepping down or stretching intervals are legitimate monitored experiments your prescriber structures with revert thresholds — not solo improvisations.
Can I take semaglutide or tirzepatide every 10–14 days in maintenance?
Extended intervals exist in individualized practice and remain off-label with limited comparative evidence — an option to discuss with your prescriber, never a self-adjustment.
Why does maintenance cost more on some plans?
Dose-tier programs bill your dose’s rung indefinitely — often the upper rungs — while flat dose-proof plans price month 30 like month 3; over a maintenance decade the architectures diverge by five figures.